^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20 inhibitor

    Related drugs:
    2d
    Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. (PubMed, Med)
    Our findings define a distinct immune signature in refractory MG, identify potential biomarkers of treatment resistance, and highlight plasma cell depletion, IL-6 or complement inhibition, and Treg expansion as promising therapeutic avenues.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CLU (Clusterin) • CD40 (CD40 Molecule)
    |
    Rituxan (rituximab)
    3d
    SIERRA: Efficiency of a Tight Monitoring by a Nurse Practitioner of Rheumatoid Arthritis (RA) Patients in Remission (clinicaltrials.gov)
    P=N/A, N=51, Completed, University Hospital, Rouen | N=88 --> 51 | Unknown status --> Completed
    Trial completion • Enrollment change
    |
    Rituxan (rituximab)
    3d
    LTFURITUX3: Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial (clinicaltrials.gov)
    P3, N=80, Completed, University Hospital, Rouen | Unknown status --> Completed
    Trial completion • HEOR
    |
    Rituxan (rituximab)
    3d
    Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Columbia University | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> May 2025
    Trial completion date • Trial primary completion date • Adverse events • Checkpoint inhibition
    |
    Rituxan (rituximab) • Actemra IV (tocilizumab)
    3d
    Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Hackensack Meridian Health | Trial completion date: Oct 2025 --> Jul 2026
    Trial completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide
    4d
    OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=904, Active, not recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2029 --> Sep 2029
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)
    4d
    Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B-Cell Lymphomas Treated With Rituximab. (PubMed, Immunology)
    The infected lymphoma patients also had expanded γδ T-cell populations. This study supports the notion of latent, reactivatable N. mikurensis infections.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PRF1 (Perforin 1)
    |
    Rituxan (rituximab)
    4d
    iMATRIX GLO: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2029 --> Nov 2032 | Trial primary completion date: May 2029 --> Nov 2029
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    4d
    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, Johns Hopkins University
    New P4 trial
    |
    Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab)
    4d
    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    5d
    Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    gemcitabine • Rituxan (rituximab) • ifosfamide • oxaliplatin • etoposide IV • mesna • Duoenda (mitoxantrone liposomal)
    5d
    Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation. (PubMed, Blood Adv)
    Given the favorable toxicity profile of mosunetuzumab, and rapid and durable complete responses observed in this cohort, further investigation of mosunetuzumab for the treatment of RT, as monotherapy and in combination with other novel agents or chemotherapy, is warranted. NCT02500407.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Lunsumio (mosunetuzumab-axgb)